Clinical Trial Update: A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update describing a Phase 1/2 study evaluating CD19-targeted immunotherapy T cells in patients with relapsed or refractory CD19+ B-cell leukemi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• CD19-targeted immunotherapy T cells

Snippet

Sponsor: Shanghai GeneChem Co., Ltd. | Conditions: Leukemia, B-Cell | Phase 1, Phase 2 | Status: UNKNOWN